AbbVie Inc. 10-Q Summary: Q2 2026
Business Context and Reporting Period
This summary covers AbbVie Inc.'s unaudited quarterly report (Form 10-Q) for the period ended June 30, 2026. AbbVie operates as a single global business segment focused on immunology, neuroscience, oncology, and aesthetics. The company is a large accelerated filer with 1,767 million shares of common stock outstanding as of July 27, 2026.
Key Financial Metrics
| Metric (in millions) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Net Revenues | $16,990 | $15,423 | $31,992 | $28,766 |
| Operating Earnings | $6,432 | $4,894 | $10,422 | $8,627 |
| Net Earnings (Attributable to AbbVie) | $3,613 | $938 | $4,308 | $2,224 |
| Diluted EPS | $2.03 | $0.52 | $2.42 | $1.24 |
| Operating Cash Flow (YTD) | $7,265 | $6,788 | - | - |
| Free Cash Flow (YTD) | $6,678 | $6,284 | - | - |
| Total Debt (Long-term + Current) | $70,822 | - | - | - |
| Cash and Equivalents | $6,569 | - | - | - |
Note: Free Cash Flow calculated as Operating Cash Flow minus Capital Expenditures ($587M YTD 2026, $504M YTD 2025). Total Debt includes $8,341M current portion and $62,481M long-term debt as of June 30, 2026.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 10.2% in Q2 and 11.2% YTD compared to 2025. On a constant currency basis, growth was 9.5% (Q2) and 9.9% (YTD).
- Profitability Surge: Net earnings attributable to AbbVie increased significantly, driven by higher operating earnings and a reduced effective tax rate (15% in Q2 2026 vs. 39% in Q2 2025).
- Product Performance:
- Immunology: Skyrizi revenues grew 24% (Q2) and 27% (YTD); Rinvoq grew 25% (Q2) and 24% (YTD). Humira declined 36% (Q2) and 37% (YTD) due to biosimilar competition.
- Neuroscience: Vraylar, Ubrelvy, and Qulipta showed double-digit growth. Vyalev revenues increased >100%.
- Oncology: Venclexta and Elahere grew, while Imbruvica declined 29% (Q2) due to pricing and demand headwinds.
- Non-GAAP Items: Other expense, net included a $3.9 billion charge YTD 2026 related to the change in fair value of contingent consideration liabilities, compared to $4.3 billion in the prior year.
Guidance, Outlook, and Risks
- Strategic Acquisitions: In June 2026, AbbVie announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion, expected to close in Q3 2026. A $10.0 billion term loan facility was secured to fund this transaction.
- Regulatory Environment: AbbVie entered a voluntary agreement with the U.S. government in January 2026, pledging $100 billion in U.S. R&D and capital investments over the next decade in exchange for a three-year exemption from tariffs and price mandates. Botox was selected for Medicare price negotiation starting in 2028.
- Capital Allocation: The company declared a quarterly dividend of $1.73 per share (up from $1.64 in Q2 2025). Remaining stock repurchase authorization was approximately $1.8 billion as of June 30, 2026.
- Risks: Significant litigation risks remain regarding opioid liability (Allergan), breast implant (ALCL) claims, and antitrust matters (Niaspan, Humira rebating). Intellectual property litigation continues for Ubrelvy and Qulipta.
Investor Verification Checklist
- Apogee Acquisition: Verify the closing timeline and regulatory approval status for the $10.9 billion Apogee Therapeutics acquisition.
- Contingent Consideration: Review the sensitivity of the $27.5 billion contingent consideration liability to changes in Skyrizi sales projections and discount rates.
- Humira Decline: Assess the trajectory of Humira revenue decline and the sufficiency of Skyrizi and Rinvoq growth to offset the loss.
- Debt Maturity: Confirm the company's ability to service $70.8 billion in total debt, including the new $10 billion term loan facility for Apogee.
- Regulatory Pricing: Monitor the impact of the Inflation Reduction Act and the specific inclusion of Botox in Medicare price negotiations beginning in 2028.